Sheng X, Liu C, Yan G, Li G, Liu J, Yang Y, et al
Primary outcomes were risk of developing AP, need for parenteral nutrition, systemic complications (sepsis, systemic inflammatory response syndrome, shock, mechanical ventilation, acute kidney injury), and local pancreatic complications
For individuals taking glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity), or the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound), maintaining adequate magnesium status may be particularly important
Abstract Akkermansia muciniphila is a promising next-generation beneficial microbe due to its natural presence in the mucus layer of the gut, its symbiotic ability to degrade mucus, and its capacity to improve the intestinal barrier function
doi: 10.1002/brb3.250
What about Mounjaro